Respiratory Syncytial Virus (RSV) Market to Register Incremental Growth by 2032 – DelveInsight | Key Players – Pfizer (PF-06928316), AstraZeneca/Sanofi (Beyfortus (nirsevimab)), GSK (GSK3844766A)

September 17 05:18 2022
Respiratory Syncytial Virus (RSV) Market to Register Incremental Growth by 2032 - DelveInsight | Key Players - Pfizer (PF-06928316), AstraZeneca/Sanofi (Beyfortus (nirsevimab)), GSK (GSK3844766A)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key companies are working in the Respiratory Syncytial Virus (RSV) therapeutics landscape. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. The Respiratory Syncytial Virus (RSV) Market Size is anticipated to increase in the coming years owing to the rise in the incident population and the launch of emerging therapies.

DelveInsight’s “Respiratory Syncytial Virus (RSV) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Respiratory Syncytial Virus Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Respiratory Syncytial Virus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Respiratory Syncytial Virus (RSV): An Overview

Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults.

Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. 

Respiratory Syncytial Virus (RSV) Market Key Facts

• According to the Centers for Disease Control and Prevention (CDC), over 57,000 hospitalizations, 500,000 emergency department visits, and 1.5 million outpatient clinic visits among children.

• As per the study titled conducted by Salma Abbas et al. (2017), RSV is a common infectious complication of transplantation, with an incidence of up to 12% in hematopoietic stem cell transplant (HSCT) patients, and 16% in adult lung transplant recipients (LTRs).

Respiratory Syncytial Virus (RSV) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Respiratory Syncytial Virus market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Respiratory Syncytial Virus market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Respiratory Syncytial Virus (RSV) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Respiratory Syncytial Virus (RSV) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory Syncytial Virus market or expected to get launched during the study period. The analysis covers Respiratory Syncytial Virus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Respiratory Syncytial Virus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Developments in the Respiratory Syncytial Virus (RSV) Therapeutics Market

• In March 2022, Pfizer Inc. (NYSE:PFE) announced that FDA had granted Breakthrough Therapy Designation for its Respiratory Syncytial Virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, for the prevention of RSV in infants from birth up to six months of age by active immunization of pregnant women. 

• On September 16, 2022, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for AstraZeneca and Sanofi’s Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

As per DelveInsight, the Respiratory Syncytial Virus (RSV) market size is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

Learn how the Respiratory Syncytial Virus (RSV) Therapeutics Market will evolve in the coming years:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market

Respiratory Syncytial Virus (RSV) Therapeutics Analysis

There are approx. 50+ key companies which are developing therapies for Respiratory Syncytial Virus (RSV). Currently, GlaxoSmithKline has its Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Respiratory Syncytial Virus (RSV) Therapeutics Market include:

GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, AstraZeneca, and others.

Respiratory Syncytial Virus (RSV) Emerging Drugs

• GSK3844766A: GlaxoSmithKline

• Nirsevimab (MEDI-8897): MedImmune

• Sisunatovir: ReViral

• AK0529

• EDP-938

• RSV preF vaccine

And many more

Further product details are provided in the report. Download the sample Report to get more detailed insights at:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Respiratory Syncytial Virus Competitive Intelligence Analysis

4. Respiratory Syncytial Virus Market Overview at a Glance

5. Respiratory Syncytial Virus Disease Background and Overview

6. Respiratory Syncytial Virus Patient Journey

7. Respiratory Syncytial Virus Epidemiology and Patient Population

8. Respiratory Syncytial Virus Treatment Algorithm, Current Treatment, and Medical Practices

9. Respiratory Syncytial Virus Unmet Needs

10. Key Endpoints of Respiratory Syncytial Virus Treatment

11. Respiratory Syncytial Virus Marketed Products

12. Respiratory Syncytial Virus Emerging Therapies

13. Respiratory Syncytial Virus Seven Major Market Analysis

14. Attribute Analysis

15. Respiratory Syncytial Virus Market Outlook (7 major markets)

16. Respiratory Syncytial Virus Access and Reimbursement Overview

17. KOL Views on the Respiratory Syncytial Virus Market.

18. Respiratory Syncytial Virus Market Drivers

19. Respiratory Syncytial Virus Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Clot Management Devices Market
“Clot Management Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Clot Management Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Clot Management Devices market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/